Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells

Objective: Despite the promise of PARP inhibitors (PARPi) for treating <i>BRCA1/2</i> mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell cycle may be synergistic and ov...

Full description

Bibliographic Details
Main Authors: Brian T. Burgess, Abigail M. Anderson, J. Robert McCorkle, Jianrong Wu, Frederick R. Ueland, Jill M. Kolesar
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Diagnostics
Subjects:
olaparib
parp
atr
chk1
resistance
brca1
ovarian cancer
inhibitor
uwb1.289
uwb1.289 + brca
Online Access:https://www.mdpi.com/2075-4418/10/2/121

Internet

https://www.mdpi.com/2075-4418/10/2/121

Similar Items